Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors

Keyphrases

• Recombinant Adeno-associated Virus (rAAV) 100%
• High Titer 100%
• Virus Serotype 100%
• High Potency 100%
• Serotype 3 100%
• Adenovirus 89%
• Capsid 26%
• Rep Protein 26%
• Inverted Terminal Repeat 26%
• Transduction Efficiency 21%
• ITR2 15%
• AAV2 10%
• Nonhuman Primate 5%
• Threonine 5%
• Hepatocytes 5%
• Relative Contribution 5%
• Tropism 5%
• Human Liver 5%
• Recombinant Vector 5%
• Liver Tumor 5%
• Human Gene Therapy 5%
• Double mutant 5%
• Primary Hepatocytes 5%
• Human Primates 5%
• Trans-acting 5%
• Cis-acting 5%
• AAV Serotypes 5%
• Vector Transduction 5%
• Human Hepatocellular Carcinoma Cell Line 5%
• Helper Plasmid 5%
• Vector Production 5%
• Liver Cancer Cell Lines 5%
• Human Liver Cancer Cells 5%

Biochemistry, Genetics and Molecular Biology

• Titer 100%
• Recombinant 100%
• Adeno Associated Virus 100%
• Serotype 100%
• Capsid 21%
• Inverted Terminal Repeat 21%
• Hepatocyte 8%
• Gene Therapy 4%
• Cancer Cell 4%
• Plasmid 4%
• Adeno Associated Virus Vector 4%
• Serine 4%
• Threonine 4%

Immunology and Microbiology

• Serotype 100%
• Titer 100%
• Adeno Associated Virus 100%
• Capsid 21%
• Inverted Terminal Repeat 21%
• In Vitro 8%
• Adeno-Associated Virus 4%
• Plasmid 4%
• Adeno Associated Virus Vector 4%
• Hepatocellular Carcinoma Cell Line 4%
• Liver Cancer Cell Line 4%
• Serine 4%
• Threonine 4%